Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Djordjevic, M. (7102319301)"

Filter results by typing the first few letters
Now showing 1 - 10 of 10
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    AMBIGUOUS GENITALIA AND LISSENCEPHALY IN A 46,XY NEONATE WITH A NOVEL VARIANT OF ARISTALESS GENE
    (2021)
    Basa, Mihail (57217286306)
    ;
    Vukovic, R. (37027529000)
    ;
    Sarajlija, A. (26027638400)
    ;
    Milenkovic, T. (55889872600)
    ;
    Djordjevic, M. (7102319301)
    ;
    Vucetic, B. (57947350900)
    ;
    Martic, J. (19639196900)
    Introduction. Disorders of sexual development can present isolated or as a part of complex genetic syndromes. Case presentation. A newborn with ambiguous genitalia and prenatally diagnosed brain malformations was referred to our hospital. Prenatal ultrasound examination and MRI showed lissencephaly and absence of the corpus callosum. At admission, physical examination revealed microphallus, hypospadia and complete fusion of labioscrotal folds with nonpalpable gonads, normal blood pressure and serum biochemistry. Cortisol level was normal (201 nmol/L), testosterone elevated (14.4 nmol/L), FSH 0.1 IU/L, LH 0.7 IU/L, estradiol 241 pmol/L. Seizures were noted on the 2nd day and the child was started on anticonvulsives. When 17-OHP level results came back elevated (200 nmol/L), ACTH test was performed and the child was started on hydrocortisone and fludrocortisone treatment. Congenital adrenal hyperplasia became unlikely when karyotype result showed normal male karyotype (46, XY, SRY+) with no Mullerian structures seen on ultrasonographic exam. As association of ambiguous genitalia and lissencephaly strongly suggested a mutual genetic background, diagnosis of X-linked lissencephaly with ambiguous genitalia (X-LAG) became apparent. Conclusions. The presented case highlights the importance of looking at the whole clinical picture instead of separate isolated findings with emphasis on patient-centered approach guided by clinical findings and patient history. © 2021, Acta Endocrinologica Foundation. All rights reserved.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    AMBIGUOUS GENITALIA AND LISSENCEPHALY IN A 46,XY NEONATE WITH A NOVEL VARIANT OF ARISTALESS GENE
    (2021)
    Basa, Mihail (57217286306)
    ;
    Vukovic, R. (37027529000)
    ;
    Sarajlija, A. (26027638400)
    ;
    Milenkovic, T. (55889872600)
    ;
    Djordjevic, M. (7102319301)
    ;
    Vucetic, B. (57947350900)
    ;
    Martic, J. (19639196900)
    Introduction. Disorders of sexual development can present isolated or as a part of complex genetic syndromes. Case presentation. A newborn with ambiguous genitalia and prenatally diagnosed brain malformations was referred to our hospital. Prenatal ultrasound examination and MRI showed lissencephaly and absence of the corpus callosum. At admission, physical examination revealed microphallus, hypospadia and complete fusion of labioscrotal folds with nonpalpable gonads, normal blood pressure and serum biochemistry. Cortisol level was normal (201 nmol/L), testosterone elevated (14.4 nmol/L), FSH 0.1 IU/L, LH 0.7 IU/L, estradiol 241 pmol/L. Seizures were noted on the 2nd day and the child was started on anticonvulsives. When 17-OHP level results came back elevated (200 nmol/L), ACTH test was performed and the child was started on hydrocortisone and fludrocortisone treatment. Congenital adrenal hyperplasia became unlikely when karyotype result showed normal male karyotype (46, XY, SRY+) with no Mullerian structures seen on ultrasonographic exam. As association of ambiguous genitalia and lissencephaly strongly suggested a mutual genetic background, diagnosis of X-linked lissencephaly with ambiguous genitalia (X-LAG) became apparent. Conclusions. The presented case highlights the importance of looking at the whole clinical picture instead of separate isolated findings with emphasis on patient-centered approach guided by clinical findings and patient history. © 2021, Acta Endocrinologica Foundation. All rights reserved.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Genetic characterization of GSD I in Serbian population revealed unexpectedly high incidence of GSD Ib and 3 novel SLC37A4 variants
    (2018)
    Skakic, A. (57095918200)
    ;
    Djordjevic, M. (7102319301)
    ;
    Sarajlija, A. (26027638400)
    ;
    Klaassen, K. (54959837700)
    ;
    Tosic, N. (15729686900)
    ;
    Kecman, B. (23034935300)
    ;
    Ugrin, M. (56554098500)
    ;
    Spasovski, V. (26655022200)
    ;
    Pavlovic, S. (7006514877)
    ;
    Stojiljkovic, M. (35095552600)
    Glycogen storage disease (GSD) type I is inborn metabolic disease characterized by accumulation of glycogen in multiple organs. We analyzed 38 patients with clinical suspicion of GSD I using Sanger and next-generation sequencing (NGS). We identified 28 GSD Ib and 5 GSD Ia patients. In 5 patients, GSD III, VI, IX, cholesteryl-ester storage disease and Shwachman-Diamond syndrome diagnoses were set using NGS. Incidences for GSD Ia and GSD Ib were estimated at 1:172 746 and 1:60 461 live-births, respectively. Two variants were identified in G6PC gene: c.247C>T (p.Arg83Cys) and c.518T>C (p.Leu173Pro). In SLC37A4 gene, 6 variants were detected. Three previously reported variants c.81T>A (p.Asn27Lys), c.162C>A (p.Ser54Arg) and c.1042_1043delCT (p.Leu348Valfs*53) accounted for 87% of all analyzed alleles. Computational, transcription studies and/or clinical presentation in patients confirmed pathogenic effect of 3 novel variants: c.248G>A (p.Gly83Glu), c.404G>A (p.Gly135Asp) and c.785G>A (p.Ser263Glyfs*33 or p.Gly262Asp). In the cohort, hepatomegaly, hypoglycemia and failure to thrive were the most frequent presenting signs of GSD Ia, while hepatomegaly and recurrent bacterial infections were clinical hallmarks of GSD Ib. All GSD Ib patients developed neutropenia while 20.6% developed inflammatory bowel disease. Our study revealed the highest worldwide incidence of GSD Ib. Furthermore, description of 3 novel variants will facilitate medical genetic practice. © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Genetic characterization of GSD I in Serbian population revealed unexpectedly high incidence of GSD Ib and 3 novel SLC37A4 variants
    (2018)
    Skakic, A. (57095918200)
    ;
    Djordjevic, M. (7102319301)
    ;
    Sarajlija, A. (26027638400)
    ;
    Klaassen, K. (54959837700)
    ;
    Tosic, N. (15729686900)
    ;
    Kecman, B. (23034935300)
    ;
    Ugrin, M. (56554098500)
    ;
    Spasovski, V. (26655022200)
    ;
    Pavlovic, S. (7006514877)
    ;
    Stojiljkovic, M. (35095552600)
    Glycogen storage disease (GSD) type I is inborn metabolic disease characterized by accumulation of glycogen in multiple organs. We analyzed 38 patients with clinical suspicion of GSD I using Sanger and next-generation sequencing (NGS). We identified 28 GSD Ib and 5 GSD Ia patients. In 5 patients, GSD III, VI, IX, cholesteryl-ester storage disease and Shwachman-Diamond syndrome diagnoses were set using NGS. Incidences for GSD Ia and GSD Ib were estimated at 1:172 746 and 1:60 461 live-births, respectively. Two variants were identified in G6PC gene: c.247C>T (p.Arg83Cys) and c.518T>C (p.Leu173Pro). In SLC37A4 gene, 6 variants were detected. Three previously reported variants c.81T>A (p.Asn27Lys), c.162C>A (p.Ser54Arg) and c.1042_1043delCT (p.Leu348Valfs*53) accounted for 87% of all analyzed alleles. Computational, transcription studies and/or clinical presentation in patients confirmed pathogenic effect of 3 novel variants: c.248G>A (p.Gly83Glu), c.404G>A (p.Gly135Asp) and c.785G>A (p.Ser263Glyfs*33 or p.Gly262Asp). In the cohort, hepatomegaly, hypoglycemia and failure to thrive were the most frequent presenting signs of GSD Ia, while hepatomegaly and recurrent bacterial infections were clinical hallmarks of GSD Ib. All GSD Ib patients developed neutropenia while 20.6% developed inflammatory bowel disease. Our study revealed the highest worldwide incidence of GSD Ib. Furthermore, description of 3 novel variants will facilitate medical genetic practice. © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Genotype–phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II
    (2017)
    Dvorakova, L. (57193618126)
    ;
    Vlaskova, H. (6503896226)
    ;
    Sarajlija, A. (26027638400)
    ;
    Ramadza, D.P. (26436064300)
    ;
    Poupetova, H. (6602750390)
    ;
    Hruba, E. (59776862800)
    ;
    Hlavata, A. (6603241185)
    ;
    Bzduch, V. (7003872700)
    ;
    Peskova, K. (6506780980)
    ;
    Storkanova, G. (6506437118)
    ;
    Kecman, B. (23034935300)
    ;
    Djordjevic, M. (7102319301)
    ;
    Baric, I. (55197502200)
    ;
    Fumic, K. (6602185534)
    ;
    Barisic, I. (7003820573)
    ;
    Reboun, M. (56605028700)
    ;
    Kulhanek, J. (56830300900)
    ;
    Zeman, J. (7101979492)
    ;
    Magner, M. (25522358400)
    Mucopolysaccharidosis type II (Hunter syndrome, MPS II, OMIM 309900) is an X-linked lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase (IDS). We analyzed clinical and laboratory data from 44 Slavic patients with this disease. In total, 21 Czech, 7 Slovak, 9 Croatian and 7 Serbian patients (43 M/1 F) were included in the study (median age 11.0 years, range 1.2–43 years). Birth prevalence ranged from 1:69,223 (Serbia) to 1:192,626 (Czech Rep.). In the majority of patients (71%), the disease manifested in infancy. Cognitive functions were normal in 10 patients. Four, six and 24 patients had mild, moderate, and severe developmental delay, respectively, typically subsequent to developmental regression (59%). Residual enzyme activity showed no predictive value, and estimation of glycosaminoglycans (GAGs) had only limited importance for prognosis. Mutation analysis performed in 36 families led to the identification of 12 novel mutations, eight of which were small deletions/insertions. Large deletions/rearrangements and all but one small deletion/insertion led to a severe phenotype. This genotype–phenotype correlation was also identified in six cases with recurrent missense mutations. Based on patient genotype, the severity of the disease may be predicted with high probability in approximately half of MPS II patients. © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Genotype–phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II
    (2017)
    Dvorakova, L. (57193618126)
    ;
    Vlaskova, H. (6503896226)
    ;
    Sarajlija, A. (26027638400)
    ;
    Ramadza, D.P. (26436064300)
    ;
    Poupetova, H. (6602750390)
    ;
    Hruba, E. (59776862800)
    ;
    Hlavata, A. (6603241185)
    ;
    Bzduch, V. (7003872700)
    ;
    Peskova, K. (6506780980)
    ;
    Storkanova, G. (6506437118)
    ;
    Kecman, B. (23034935300)
    ;
    Djordjevic, M. (7102319301)
    ;
    Baric, I. (55197502200)
    ;
    Fumic, K. (6602185534)
    ;
    Barisic, I. (7003820573)
    ;
    Reboun, M. (56605028700)
    ;
    Kulhanek, J. (56830300900)
    ;
    Zeman, J. (7101979492)
    ;
    Magner, M. (25522358400)
    Mucopolysaccharidosis type II (Hunter syndrome, MPS II, OMIM 309900) is an X-linked lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase (IDS). We analyzed clinical and laboratory data from 44 Slavic patients with this disease. In total, 21 Czech, 7 Slovak, 9 Croatian and 7 Serbian patients (43 M/1 F) were included in the study (median age 11.0 years, range 1.2–43 years). Birth prevalence ranged from 1:69,223 (Serbia) to 1:192,626 (Czech Rep.). In the majority of patients (71%), the disease manifested in infancy. Cognitive functions were normal in 10 patients. Four, six and 24 patients had mild, moderate, and severe developmental delay, respectively, typically subsequent to developmental regression (59%). Residual enzyme activity showed no predictive value, and estimation of glycosaminoglycans (GAGs) had only limited importance for prognosis. Mutation analysis performed in 36 families led to the identification of 12 novel mutations, eight of which were small deletions/insertions. Large deletions/rearrangements and all but one small deletion/insertion led to a severe phenotype. This genotype–phenotype correlation was also identified in six cases with recurrent missense mutations. Based on patient genotype, the severity of the disease may be predicted with high probability in approximately half of MPS II patients. © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Molecular and phenotypic characteristics of seven novel mutations causing branched-chain organic acidurias
    (2016)
    Stojiljkovic, M. (35095552600)
    ;
    Klaassen, K. (54959837700)
    ;
    Djordjevic, M. (7102319301)
    ;
    Sarajlija, A. (26027638400)
    ;
    Brasil, S. (49660918100)
    ;
    Kecman, B. (23034935300)
    ;
    Grkovic, S. (8710432500)
    ;
    Kostic, J. (57159483500)
    ;
    Rodriguez-Pombo, P. (6602708464)
    ;
    Desviat, L.R. (7003747320)
    ;
    Pavlovic, S. (7006514877)
    ;
    Perez, B. (7101818958)
    Specific mitochondrial enzymatic deficiencies in the catabolism of branched-chain amino acids cause methylmalonic aciduria (MMA), propionic acidemia (PA) and maple syrup urine disease (MSUD). Disease-causing mutations were identified in nine unrelated branched-chain organic acidurias (BCOA) patients. We detected eight previously described mutations: p.Asn219Tyr, p.Arg369His p.Val553Glyfs*17 in MUT, p.Thr198Serfs*6 in MMAA, p.Ile144_Leu181del in PCCB, p.Gly288Valfs*11, p.Tyr438Asn in BCKDHA and p.Ala137Val in BCKDHB gene. Interestingly, we identified seven novel genetic variants: p.Leu549Pro, p.Glu564*, p.Leu641Pro in MUT, p.Tyr206Cys in PCCB, p.His194Arg, p.Val298Met in BCKDHA and p.Glu286_Met290del in BCKDHB gene. In silico and/or eukaryotic expression studies confirmed pathogenic effect of all novel genetic variants. Aberrant enzymes p.Leu549Pro MUT, p.Leu641Pro MUT and p.Tyr206Cys PCCB did not show residual activity in activity assays. In addition, activity of MUT enzymes was not rescued in the presence of vitamin B12 precursor in vitro which was in accordance with non-responsiveness or partial responsiveness of patients to vitamin B12 therapy. Our study brings the first molecular genetic data and detailed phenotypic characteristics for MMA, PA and MSUD patients for Serbia and the whole South-Eastern European region. Therefore, our study contributes to the better understanding of molecular landscape of BCOA in Europe and to general knowledge on genotype–phenotype correlation for these rare diseases. © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Molecular and phenotypic characteristics of seven novel mutations causing branched-chain organic acidurias
    (2016)
    Stojiljkovic, M. (35095552600)
    ;
    Klaassen, K. (54959837700)
    ;
    Djordjevic, M. (7102319301)
    ;
    Sarajlija, A. (26027638400)
    ;
    Brasil, S. (49660918100)
    ;
    Kecman, B. (23034935300)
    ;
    Grkovic, S. (8710432500)
    ;
    Kostic, J. (57159483500)
    ;
    Rodriguez-Pombo, P. (6602708464)
    ;
    Desviat, L.R. (7003747320)
    ;
    Pavlovic, S. (7006514877)
    ;
    Perez, B. (7101818958)
    Specific mitochondrial enzymatic deficiencies in the catabolism of branched-chain amino acids cause methylmalonic aciduria (MMA), propionic acidemia (PA) and maple syrup urine disease (MSUD). Disease-causing mutations were identified in nine unrelated branched-chain organic acidurias (BCOA) patients. We detected eight previously described mutations: p.Asn219Tyr, p.Arg369His p.Val553Glyfs*17 in MUT, p.Thr198Serfs*6 in MMAA, p.Ile144_Leu181del in PCCB, p.Gly288Valfs*11, p.Tyr438Asn in BCKDHA and p.Ala137Val in BCKDHB gene. Interestingly, we identified seven novel genetic variants: p.Leu549Pro, p.Glu564*, p.Leu641Pro in MUT, p.Tyr206Cys in PCCB, p.His194Arg, p.Val298Met in BCKDHA and p.Glu286_Met290del in BCKDHB gene. In silico and/or eukaryotic expression studies confirmed pathogenic effect of all novel genetic variants. Aberrant enzymes p.Leu549Pro MUT, p.Leu641Pro MUT and p.Tyr206Cys PCCB did not show residual activity in activity assays. In addition, activity of MUT enzymes was not rescued in the presence of vitamin B12 precursor in vitro which was in accordance with non-responsiveness or partial responsiveness of patients to vitamin B12 therapy. Our study brings the first molecular genetic data and detailed phenotypic characteristics for MMA, PA and MSUD patients for Serbia and the whole South-Eastern European region. Therefore, our study contributes to the better understanding of molecular landscape of BCOA in Europe and to general knowledge on genotype–phenotype correlation for these rare diseases. © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Tetraploidy in a 26-month-old girl (cytogenetic and molecular studies)
    (2002)
    Guc-Scekic, Marija (6602359789)
    ;
    Milasin, J. (6603015594)
    ;
    Stevanovic, M. (57744254000)
    ;
    Stojanov, L.J. (6701433358)
    ;
    Djordjevic, M. (7102319301)
    Liveborn infants with tetraploidy are very rare in human pregnancies and usually die during the first days or months. Seven cases of liveborn infants with tetraploidy have previously been reported. Among them only two 92, XXXX infants survived for longer than 12 months. Here we report on the case of a 26-month-old girl with tetraploidy. The main clinical features of tetraploidy are facial dysmorphism, severely delayed growth and developmental delay. On the basis of molecular studies we discuss the possible origin of the additional chromosome sets in our proband. To our knowledge, this infant is the first reported case of tetraploidy who lived up to 26 months.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Tetraploidy in a 26-month-old girl (cytogenetic and molecular studies)
    (2002)
    Guc-Scekic, Marija (6602359789)
    ;
    Milasin, J. (6603015594)
    ;
    Stevanovic, M. (57744254000)
    ;
    Stojanov, L.J. (6701433358)
    ;
    Djordjevic, M. (7102319301)
    Liveborn infants with tetraploidy are very rare in human pregnancies and usually die during the first days or months. Seven cases of liveborn infants with tetraploidy have previously been reported. Among them only two 92, XXXX infants survived for longer than 12 months. Here we report on the case of a 26-month-old girl with tetraploidy. The main clinical features of tetraploidy are facial dysmorphism, severely delayed growth and developmental delay. On the basis of molecular studies we discuss the possible origin of the additional chromosome sets in our proband. To our knowledge, this infant is the first reported case of tetraploidy who lived up to 26 months.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback